Exogenous Hormones Associate With Reduced Dementia Risk in UK Biobank Cohort

Exogenous Hormones and the Aging Brain

The clinical management of female patients across the reproductive lifespan requires a careful balancing of hormonal interventions, from contraception in early adulthood to the mitigation of menopausal symptoms in later years [1, 2]. While the cardiovascular and metabolic effects of these therapies are well-documented in established clinical guidelines, their long-term impact on neurological health remains a subject of intense debate [3, 4, 5]. Clinicians frequently face questions regarding the safety and secondary effects of exogenous hormones, yet definitive data on neuroprotection or cognitive risk have been inconsistent. Understanding these associations is critical for informed shared decision-making, particularly as the prevalence of neurodegenerative conditions continues to grow [6]. A large-scale cohort study now provides new evidence regarding how the duration and timing of hormone use may influence the risk of incident dementia.

Large-Scale Cohort Analysis of Hormonal Exposure

Researchers conducted a robust longitudinal analysis using data from 233,896 female participants enrolled in the UK Biobank to clarify the relationship between exogenous hormone exposure and long-term neurodegenerative risk. To evaluate these associations, the study utilized multivariate Cox proportional hazard regression models, a statistical method that calculates the risk of an event occurring over time while adjusting for confounding variables such as age, socioeconomic status, and comorbidities. The analysis specifically focused on the incidence of all-cause dementia, Alzheimer's disease, and vascular dementia. Beyond diagnostic incidence, the study investigated how hormone use correlates with objective cognitive function through linear regression models, which assess the strength of the relationship between an exposure and a continuous outcome like test scores.

Quantifying the Reduction in Dementia Risk

The study revealed that oral contraceptive use was associated with a 19.4 percent reduction in the risk of all-cause dementia (HR 0.806; 95% CI, 0.724 to 0.897). When the analysis was narrowed to specific dementia subtypes, the risk reduction remained statistically significant, with Alzheimer's disease risk decreasing by 23.3 percent (HR 0.767; 95% CI, 0.659 to 0.893) and vascular dementia risk by 26.5 percent (HR 0.735; 95% CI, 0.578 to 0.934). These findings suggest that the hormonal modulation provided by oral contraceptives during reproductive years may have long-term implications for both cerebrovascular and neurocognitive health, potentially offering a degree of resilience against the proteinopathies and ischemic changes associated with aging. For the practicing clinician, these data provide a quantitative basis for discussing the long-term neurological profile of patients with a history of contraceptive use.

Duration Effects and Structural Brain Mediators

The researchers found that the duration of oral contraceptive use showed a non-linear, J-shaped association with the risks of all-cause dementia and Alzheimer's disease, suggesting that the protective association is not strictly cumulative but may fluctuate based on the total length of exposure. To identify the potential biological pathways involved, the researchers employed mediation models (statistical tests used to determine if the effect of an independent variable, such as hormone use, is explained by an intervening biological factor). These models identified the bilateral pallidum and left thalamus proper as potential mediators in the relationship between the duration of oral contraceptive use and cognitive performance. The pallidum and thalamus are critical subcortical structures involved in motor control and the relay of sensory information; their role as mediators suggests that hormonal exposure may influence cognitive health by preserving the structural integrity of these deep gray matter nuclei. Furthermore, hormone replacement therapy was associated with a 10.3 percent lower risk of all-cause dementia (HR 0.897; 95% CI, 0.811 to 0.992) and a 19.6 percent lower risk of Alzheimer's disease (HR 0.804; 95% CI, 0.696 to 0.928), reinforcing the hypothesis that exogenous hormones may play a role in maintaining cognitive reserve across the female lifespan.

References

1. Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Human Reproduction Update. 2017. doi:10.1093/humupd/dmx011

2. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 2018. doi:10.1111/bdi.12609

3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2019. doi:10.1093/eurheartj/ehz455

4. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018. doi:10.1093/eurheartj/ehy339

5. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013. doi:10.1093/eurheartj/eht151

6. Ringleb PA, Bousser MG. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovascular Diseases. 2008. doi:10.1159/000131083